Our Technology

Velanidi’s novel microelectronic medicine technology is described in patent applications pending in the United States and in jurisdictions outside the U.S.

Generally, Velanidi’s first-generation core technology platform is based on a device that is µm- or nm-scale in size, and can include integrated circuitry logic based on sub 10nm SIA transistor nodes, a sensing subsystem, a deciding subsystem, an effecting subsystem, and a power harvesting system. The sensing subsystem is designed identify pathogenic entities, including disease associated cells (for example, cancer cells, autoimmune cells, or pathological microbes) or viruses. The sensing subsystem can include at least one pad constructed of an electrically conductive material and linkers attached to the at least one pad. Each linker can also be attached to a targeting agent (for example, an antibody fragment) or a reference agent. Upon the binding of a targeting agent with an entity of interest, the information is transferred to the logic circuitry, which processes the binding event information and decides whether the entity is disease associated (for example, a disease-associated cell or virus) and requires delivery of therapeutic agents or other treatment (such as electro-ablation of the disease-associated cell). The ability to discriminate between a targeted disease-associated cell and a healthy cell, using computer logic, provides extraordinary, cellular-scale specificity of disease targeting and treatment that is absent largely from contemporary disease treatment methodologies.